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Background: In diffuse large B-cell lymphomas, gene expression profiling studies attributed a major biologic role to
non-neoplastic cells of the tumour microenvironment as its composition and characteristics were shown to predict
survival. In particular, the expression of selected genes encoding components of the extracellular matrix was
reported to be associated with clinical outcome. Nevertheless, the translation of these data into robust, routinely
applicable immunohistochemical markers is still warranted. Therefore, in this study, we analysed the combination of
the expression of the extracellular matrix components Fibronectin and SPARC on formalin-fixed paraffin embedded
tissue derived from 173 patients with DLBCL in order to recapitulate gene expression profiling data.
Results: The expression of Fibronectin and SPARC was detected in 77/173 (44.5%) and 125/173 (72.3%) cases,
respectively, and 55/173 (31.8%) cases were double positive. Patients with lymphomas expressing Fibronectin
showed significantly longer overall survival when compared to negative ones (6.3 versus 3.6 years). Moreover,
patients with double positive lymphomas also presented with significantly longer overall survival when compared
with the remaining cases (11.6 versus 3.6 years) and this combined expression of both markers results in a better
association with overall survival data than the expression of SPARC or Fibronectin taken separately (Hazard ratio
0.41, 95% confidence interval 0.17 to 0.95, p = 0.037). Finally, neither Fibronectin nor SPARC expression was
associated with any of the collected clinico-pathological parameters.
Conclusions: The combined immunohistochemical assessment of Fibronectin and SPARC, two components of the
extracellular matrix, represents an important tool for the prediction of survival in diffuse large B-cell lymphomas.
Our study suggests that translation of gene expression profiling data on tumour microenvironment into routinely
applicable immunohistochemical markers is a useful approach for a further characterization of this heterogeneous
type of lymphoma.
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Diffuse large B-cell lymphoma (DLBCL) accounts for
approximately 25-30% of non-Hodgkin lymphomas in
adults in the western countries and includes biologically
and clinically heterogeneous subgroups of tumours,
which present with distinctive outcomes [1]. The gene
expression profiling (GEP) of primary tumour samples
led to the identification of two major DLBCL subtypes
based on the similarity with maturation stages of B-cell
differentiation: those derived from activated B-cells
(non-GCB) or germinal-centre B-cell-like cells (GCB)
[2,3]. In addition to the properties of the lymphoma
cells, the composition of the tumour microenvironment
and genes expressed by non-tumour cells have also been
shown to be useful for the characterization of DLBCL.
To this regard, the DLBCL subgroup expressing de novo
CD5, which represents approximately 10% of all DLBCL
cases and carries a more aggressive behaviour, presents
with down-regulation of genes associated with extra-
cellular matrix (ECM), such as SPARC (secreted pro-
tein acidic and rich in cysteine) [4-6]. Moreover, stromal
gene signatures, which predicted survival in patients
treated with CHOP and R-CHOP, were identified in
DLBCL through the separate analysis of the neoplastic
and non-neoplastic subpopulation by means of flow cy-
tometry. In particular, a so-called stromal-1 signature
reflecting ECM deposition and histiocytic infiltration
was associated with better clinical outcome [7]. Fibro-
nectin (FN1) and SPARC were among the genes included
in this stromal-1 signature. FN1 is a 250-kDA glycopro-
tein composed of 2 similar polypeptides [8] and can
present as soluble plasma dimer, mainly released by he-
patocytes, or as an insoluble multimer, secreted by dif-
ferent cell types, such as epithelial cells, fibroblasts and
macrophages [9]. In the latter form, FN1 represents a
major component of the ECM and through its different
domains it can interact with other proteins of the ECM,
glycosaminoglicanes, as well as cell receptors, in parti-
cular integrins [8]. SPARC, also called osteonectin, is a
highly conserved 43-kDa glycoprotein which can be
expressed by osteoblasts, endothelial cells, fibroblasts,
macrophages, as well as by a variety of tumour cell types.
It functions by regulating cell adhesion, ECM remodelling,
and growth factor signalling and has been shown both to
induce tumour progression and suppress tumour growth,
depending on the tumour type [10]. Whereas the protein
expression of SPARC was shown to correlate with better
prognosis in DLBCL [7,11], the one of FN1 has not been
studied so far.
The translation of GEP data onto the protein level by
means of immunohistochemistry (IHC) represents an
important step for routine diagnostic purposes. For this
reason, in the present study we analysed the IHC ex-
pression of both FN1 and SPARC in relationship withclinic-pathological data in a large series of DLBCL on
tissue microarrays (TMA).
Results
Characteristics of patients and tumours
Our cohort of 173 patients included 94 (54.3%) men and
79 (45.7%) women. Patients ranged in age from 15 to
95 years, with a median age of 64 years. Of these, 67
(38.7%) were younger than 60 years and 106 (61.3%)
were older than 60 years. The median follow-up for
the 173 patients was 5.4 years, ranging from 0.02 to
19.35 years. Based on IHC, 67 (38.7%) cases were clas-
sified as GCB and 106 (61.3%) as non-GCB, according to
the Hans algorithm. CD5 expression was detected in 6 out
of 173 (3.5%) cases. By means of fluorescence in situ
hybridization (FISH) analysis, translocations for BCL2,
BCL6 and MYC were detected in 23 (13.3%), 31 (17.9%)
and 6 (3.5%) cases, respectively. Summary of the cha-
racteristics of tumours and patients are presented in
Tables 1 and 2.
Expression of fibronectin and SPARC in DLBCL
FN1 staining highlighted fibrous strands of the ECM
between tumour cells and 96 cases (55.5%) resulted as
FN1-low, whereas 77 cases (44.5%) as FN1-high (Figure 1).
SPARC expression was observed in non-neoplastic cells.
Out of the 173 cases, 48 (27.7%) were considered as
SPARC-low, whereas 125 cases (72.3%) contained at least
10% positive non-neoplastic cells and were classified as
SPARC-high (Figure 2). The results for the combined
expression of FN1 and SPARC showed: 55 (31.8%)
cases were FN1-high/SPARC-high, 22 (12.7%) FN1-
high/SPARC-low, 70 (40.5%) FN1-low/SPARC-high,
and 26 (15.0%) FN1-low/SPARC-low.
In a Pearson’s chi-squared test, we could not find any
significant association between the expression of SPARC
and of FN1 (p-value = 0.19). Moreover, no significant as-
sociation was found between the expression of either
ECM markers and the GCB or non-GCB phenotype,
CD5 expression, molecular aberrations for BCL2, BCL6
and MYC or the collected clinico-pathological parame-
ters (gender, tumour site, and tumour stage).
The combined expression of FN1 and SPARC correlates
with longer overall survival (OS)
In a Kaplan-Meier analysis of OS, patients with FN1-
high expression showed a significant longer OS com-
pared with patients presenting with FN1-low expression
(median survival time of 6.3 years for FN1-high cases
versus 3.6 years for FN1-low cases, p-value = 0.05). Re-
garding SPARC expression, SPARC-high cases showed
longer OS, even though this association was not signi-
ficant (median survival 5.0 years for SPARC-high cases
versus 2.5 years for SPARC-low cases, p-value = 0.083).
Table 1 Clinical characteristics of the patients
Clinical information Number (%)
Age at diagnosis Mean 61.6
Median 64
<60 years 67 (38.7)
>60 years 106 (61.3)
Gender Female 79 (45.7)
Male 94 (54.3)
Localisation Nodal only 79 (45.7)
Extranodal only 61 (35.3)
Nodal and extranodal 30 (17.3)
No data available 3 (1.7)
Stage I 26 (15.0)
II 21 (12.1)
III 16 (9.2)
IV 16 (9.2)
No data available 94 (54.3)
Chemotherapy CHOP-like regimen 72 (92.5)
Intensive regimen 2 (1.2)
VACOP 3 (1.7)
Low-intensity regimen 6 (3.5)
No treatment 2 (1.2)
Rituximab Yes 49 (28.3)
No 43 (24.9)
No data available 81 (46.8)
Rituximab (patients with
CHOP-like regimen)
Yes 45 (26.0)
No 27 (15.6)
No data available 101 (58.4)
Radiotherapy Yes 24 (13.9)
No 59 (34.1)
No data available 90 (52)
Response to treatment Complete remission 49 (28.3)
Recurrence 47 (27.2)
Death without
disease-free interval
41 (23.7)
Loss of follow-up 36 (20.8)
Table 2 Immunohistochemical and genetic characteristics
of the lymphomas
Immunohistochemical analysis Number (%)
CD10 expression Positive 49 (28.3)
Negative 124 (71.7)
BCL6 expression Positive 59 (34.1)
Negative 114 (65.9)
MUM1 expression Positive 44 (25.4)
Negative 129 (74.6)
GCB/non-GCB phenotype GCB 67 (38.7)
non-GCB 106 (61.3)
Fibronectin expression High 77 (44.5)
Low 96 (55.5)
SPARC expression High 125 (72.3)
Low 48 (27.7)
CD5 expression Positive (>20%) 6 (3.5)
Negative (<20%) 167 (96.5)
FISH analysis
Number of translocations 0 116 (67.1)
1 53 (30.6)
2 4 (2.3)
FISH for BCL2 translocation 23 (13.3)
no translocation 131 (75.7)
not evaluable 19 (11)
FISH for BCL6 translocation 31 (17.9)
no translocation 55 (31.8)
not evaluable 87 (50.3)
FISH for MYC translocation 6 (3.5)
no translocation 117 (67.6)
not evaluable 50 (28.9)
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associated with longer progression free survival (PFS)
(p-value = 0.8 and p-value = 0.2, respectively).
Moreover, double positive SPARC-high/FN1-high cases
presented with a significantly longer OS when com-
pared with the remaining ones (median survival time
of 11.6 years versus 3.6 years, p-value = 0.002) (Figure 3).
A Cox-regression analysis showed that the combination
FN1-high/SPARC-high had a significantly longer OS when
adjusted for the SPARC-high and FN1-high expressions(Hazard ratio 0.41, 95% confidence interval 0.17 to
0.95, p = 0.037).
Discussion
In previous studies, the expression of the protein SPARC
was shown to predict longer OS [7,11,12]. Nevertheless,
the IHC expression on formalin-fixed paraffin embedded
tissues of other ECM components, such as FN1 or their
combination, has not been investigated so far. In the
present study, we show that DLBCL cases with expres-
sion of FN1 present with longer OS. Moreover, in our
cohort the combined expression of FN1 and SPARC is a
better predictor for longer OS than the markers taken
separately. Since our study comprises mostly cases diag-
nosed before the introduction of Rituximab as treatment
option, only 49 patients received this drug in our cohort.
When the analysis for OS was performed in this subgroup
of patients no significant difference based on SPARC, FN1
Figure 1 Fibronectin staining highlights fibrous strands of the ECM between tumour cells of DLBCL. Four DLBCL cases with different
staining intensities are shown. A. and B. DLBCL cases scored 1 and 2, respectively, and considered as FN1-low. C. and D. DLBCL cases scored 3
and 4, respectively, and considered as FN1-high.
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due to the low number of cases (data not shown).
Our results, generated by IHC, recapitulate data from
a GEP study on a large number of DLBCL. The authors
identified several genes of the ECM, and grouped them
into so-called stromal signatures, able to predict survival
[7]. Stromal-2 signature genes included markers for
endothelial cells and key regulator for angiogenesis. In
contrast, stromal-1 signature encoded components of the
ECM, such as various collagen and laminin isoforms, as
well as FN1 and SPARC. In accordance with its role in
ECM formation, staining for FN1 localized to the fibrous
strands in our lymphomas. SPARC staining, instead,
highlighted endothelial cells and non-neoplastic cells,
which were identified as macrophages in previous studies,
based on CD68 expression [7,11]. Even though several
data suggest that the composition of ECM is of major im-
portance in the tumourigenesis, the exact functions of
SPARC and FN1 in DLBCL have not been studied so far.
To this regard, the role of SPARC could be related to its
regulatory activity in several signalling pathways, such as
TGFβ and PI3K/AKT. Moreover, SPARC has been shown
to bind to FN1 fragments and to induce matrix metallo-
proteinases (MMP) which degrade ECM components [10].
Our results, together with data derived from studies
on tumour microenvironment performed in other tu-
mour types, might open new diagnostic and therapeuticpossibilities. To this regard, both FN1 and SPARC are
being tested as biomarkers in different clinical trials
(see http://clinicaltrials.gov, identifiers: NCT01288963,
NCT01442974, NCT01566435). In addition, new thera-
peutic strategies targeting the ECM components are being
evaluated, such as specific molecules inhibiting the in-
teraction between FN1 and tumour cells or therapeutic
agents conjugated to antibodies specific for tumour envir-
onment. For example, interleukin-2 has been conjugated
to an antibody specific for the FN1 isoform containing the
extradomain-B, EDB, which is expressed during tissue re-
modelling in tumours [13,14].
In conclusion, our results show that the combined
IHC expression of FN1 and SPARC can be used in the
routine clinical practice as predictor of survival in pa-
tients suffering from DLBCL, recapitulating the data de-
rived from GEP studies. This suggests that both the
ECM component FN1 and the ECM remodelling SPARC
can influence the survival of lymphoma cells and their
interactions with the microenvironment.
Methods and patients
Case selection and construction of tissue microarray
A series of 173 DLBCL diagnosed between 1990 and
2009 were retrieved from the database of the Institute of
Surgical Pathology, University Hospital Zurich (PathoPro
software, Institute for medical software, Saarbrücken)
Figure 2 SPARC staining was detected primarily in non-tumour
cells and in endothelial cells of blood vessels. Blood vessels were
not considered in our analysis. A DLBCL case showing merely
scattered positive cells apart from few positive blood vessels and
scored negative for SPARC (SPARC-low) (A). A DLBCL case with a
high number of SPARC positive cells of the microenvironment and
considered as SPARC-high (B).
FN high
FN low SPAR
p=0.05
A B
Figure 3 Kaplan-Meier analysis showing overall survival of 173 DLBCL
(A), p = 0.05, SPARC (B), p = 0.083 and combined FN1 high/SPARC hig
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and M.T.) following the current WHO classification [1].
Collected clinical data included age, gender, tumour
site, and tumour stage. For 85 patients, data on the thera-
peutic approach were available and consisted of CHOP or
CHOP-like regimens (72 patients, 45 of them with Rituxi-
mab), intensive regimens (HyperCVAD/MTX-AraC, high-
dose MTX or M-ACOD; 2 patients, 1 of them with
Rituximab), VACOP (vincristine, adriamycin/doxorubicin,
cyclophosphamide, etoposide, and prednisone; 3 patients,
1 of them with Rituximab) or low-intensity regimen
(chlorambucil and prednisolone; 6 patients, 2 of them
with Rituximab). Two patients received no therapy. Col-
lection of survival data and follow-up was carried out in
collaboration with the Cancer Registry Zurich.
A tissue microarray (TMA) containing 2 representa-
tive tumour tissue core of 0.6 mm in diameter for each
case was constructed using formalin-fixed paraffin em-
bedded tissues, as previously described [15].
This study was in accordance with the Helsinki dec-
laration and Swiss laws and was approved by the offi-
cial authorities of the ethical committee of the Canton
Zurich (StV2-2007).
Immunohistochemistry and FISH
Staining for lymphoma classifications were carried out as
recently published [15]. Additionally, 3-μm-thick sections
of the TMA were stained in a Ventana ES instrument
(Roche’s Ventana Medical Systems, Basel, Switzerland) for
FN1 (polyclonal rabbit anti human A0245, DAKO), and
SPARC (monoclonal mouse anti-human AON-5031,
Santa-Cruz) and evaluated by two pathologists (S.B. and
D.S.). By means of CD20 staining tumour areas were iden-
tified and the presence of at least 30% of tumour cells
for each core was confirmed. MUM1/IRF4, CD10 and
BCL6 stainings were scored as negative or positive with a
cut-off at 30% and cases were classified either into GCBSPARC high
C low
FN high/SPARC high
remaining cases
p=0.083 p=0.002
C
cases separated on the basis of their expression of fibronectin
h expression (C), p = 0.002.
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as previously described [16]. For CD5, positivity was
considered when more than 20% of tumour cells
expressed this marker [5].
Regarding FN1, the staining intensity of fibrous strands
of the extracellular matrix in tumour areas was considered
[7]. Cases were scored form 1+ (negative to weak expres-
sion) to 4+ (very strong expression) and the range was
then divided into a FN1-low category (1+ and 2+) and a
FN1-high (3+ and 4+) category. For SPARC, the number
of positive non-neoplastic cells in tumour areas was
graded in 10% increments and cases were classified as
SPARC-low if less than 10% of non-neoplastic cells were
positive and as SPARC-high if at least 10% of non-
neoplastic cells were positive for SPARC, based on reports
of previous studies [11]. FN1 and SPARC staining in blood
vessels was not considered, as genes related to blood ves-
sels are not included in the stromal-1 signature [7]. FISH
analysis for BCL2, BCL6 and MYC were performed using
probes with a split signals strategy (DAKO) for all cases
on TMA, as previously described [15].
For all statistical analysis each case was averaged over
both its TMA cores.
Statistical analysis
Association of the expression of FN1 and SPARC and the
relationship between the expression of the two markers
and the clinical parameters, including gender, tumour site,
tumour stage, as well as IHC characteristics, such as posi-
tivity for CD5 and affiliation to GCB or non-GCB subtype,
were evaluated using Pearson’s chi-square tests.
Kaplan-Meier analysis was used to estimate OS and
PFS. OS was defined as the time from the lymphoma
diagnosis to death of any cause or last contact. PFS was
defined as the time from the lymphoma diagnosis to re-
currence, death or last contact. The log-rank test was
used to evaluate differences in OS and PFS between
groups. Cox-regression was used to determine the com-
bined effect of the expression of SPARC and FN1.
Statistical analysis was performed using IBM SPSS
Statistics 21 (SPSS Inc, Chicago, IL, USA). P-values ≤0.05
were considered statistically significant.
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